

Selected Tests for Rheumatic Diseases

Policy ID:	HHO-DE-MP-1084
Approved By:	Highmark Health Options – Market Leadership
Provider Notice Date:	
Original Effective Date:	N/A
Annual Approval Date:	10/2022
Last Revision Date:	10/08/2021
Products:	Medicaid
Application:	
Page Number(s):	1-5

Disclaimer

Highmark Health Options medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions.

POLICY STATEMENT

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic joint inflammation that ultimately leads to joint destruction. Diagnosis of early disease is important. While the diagnosis of RA is established primarily on clinical criteria (physical examination and radiographic evaluation), laboratory testing for cyclic citrullinated peptide antibodies may contribute to early RA diagnosis.

Definitions

Highmark Health Options (HHO) – Managed care organization serving vulnerable populations that have complex needs and qualify for Medicaid. Highmark Health Options members include individuals and families with low income, expecting mothers, children, and people with disabilities. Members pay nothing to very little for their health coverage. Highmark Health Options currently serves Delaware Medicaid: Delaware Healthy Children Program (DHCP) and Diamond State Health Plan and Health Plan Plus members.

Rheumatic Disease – Autoimmune and inflammatory diseases that cause your immune system to attack your joints, muscles, bones and organs

POLICY POSITION

The measurement of anti-cyclic citrullinated peptide (anti-CCP) antibodies may be considered medically necessary for diagnosis of RA.

The measurement of anti-CCP antibodies is considered experimental/investigational and, therefore, noncovered for all other indications. There is a lack of peer-reviewed literature regarding the effectiveness of these tests.

Autoantibody panels may be considered medically necessary when performed following confirmed ANA positivity or clinical suspicion that a rheumatologic disease is present in a child.

Autoantibody panel testing for RA in the absence of history or physical exam evidence of a rheumatologic disease is considered experimental/investigational and, therefore, noncovered. There is a lack of peer-reviewed literature regarding autoantibody panel testing in the absence of history or physical exam evidence of a rheumatologic disease.

The myositis antibody panel may be considered medically necessary for diagnosing persons with inflammatory myopathy.

The myositis antibody panel is considered experimental/investigational and, therefore, noncovered for other indications. There is a lack of peer-reviewed literature regarding the effectiveness of these tests.

PROCEDURE CODES

83516	Immunoassay For Analyte Other Than Infectious Agent Antibody Or Infectious Agent Antigen; Qualitative Or Semiquantitative, Multiple Step Method.
86200	Cyclic Citrullinated Peptide (ccp), Antibody.
86430	Rheumatoid Factor; Qualitative.
86431	Rheumatoid Factor; Quantitative.

Eligible Diagnosis Codes for Procedure Code 86200

H17.11-H17.13	H17.811-H17.813	H30.891	H30.892	H30.899
H30.90-H30.93	H54.2	H54.3	H57.11-H57.13	K11.7
L52	M05.00	M05.011	M05.012	M05.021
M05.022	M05.031	M05.032	M05.041	M05.042
M05.051	M05.052	M05.061	M05.062	M05.071
M05.072	M05.7A	M05.8A	M05.10	M05.111
M05.112	M05.121	M05.122	M05.131	M05.132
M05.141	M05.142	M05.151	M05.152	M05.161
M05.162	M05.171	M05.172	M05.19	M05.211
M05.212	M05.221	M05.222	M05.231	M05.232
M05.241	M05.242	M05.251	M05.252	M05.261
M05.262	M05.271	M05.272	M05.311	M05.312
M05.321	M05.322	M05.331	M05.332	M05.341
M05.342	M05.351	M05.352	M05.361	M05.362
M05.371	M05.372	M05.39	M05.411	M05.412

M05.421	M05.422	M05.431	M05.432	M05.441
M05.442	M05.451	M05.452	M05.461	M05.462
M05.471	M05.472	M05.49	M05.511	M05.512
M05.521	M05.522	M05.531	M05.532	M05.541
M05.542	M05.551	M05.552	M05.561	M05.562
M05.571	M05.572	M05.59	M05.611	M05.612
M05.621	M05.622	M05.631	M05.632	M05.641
M05.642	M05.651	M05.652	M05.661	M05.662
M05.671	M05.672	M05.69	M05.711	M05.712
M05.721	M05.722	M05.731	M05.732	M05.741
M05.742	M05.751	M05.752	M05.761	M05.762
M05.771	M05.772	M05.79	M05.811	M05.812
M05.821	M05.822	M05.831	M05.832	M05.841
M05.842	M05.851	M05.852	M05.861	M05.862
M05.871	M05.872	M05.89	M06.01	M06.011
M06.012	M06.021	M06.022	M06.031	M06.032
M06.041	M06.042	M06.051	M06.052	M06.061
M06.062	M06.071	M06.072	M06.08	M06.09
M06.8A	M06.211	M06.212	M06.221	M06.222
M06.231	M06.232	M06.241	M06.242	M06.251
M06.252	M06.261	M06.262	M06.271	M06.272
M06.28	M06.29	M06.311	M06.312	M06.321
M06.322	M06.331	M06.332	M06.341	M06.342
M06.351	M06.352	M06.361	M06.362	M06.371
M06.372	M06.38	M06.39	M06.4	M06.811
M06.812	M06.821	M06.822	M06.831	M06.832
M06.841	M06.842	M06.851	M06.852	M06.861
M06.862	M06.871	M06.872	M06.88	M06.89
M08.0A	M08.011	M08.012	M08.021	M08.022
M08.031	M08.032	M08.041	M08.042	M08.051
M08.052	M08.061	M08.062	M08.071	M08.072
M08.08	M08.09	M08.1	M08.2A	M08.211
M08.212	M08.221	M08.222	M08.231	M08.232
M08.241	M08.242	M08.251	M08.252	M08.261
M08.262	M08.271	M08.272	M08.28	M08.29
M08.3	M08.4A	M08.411	M08.412	M08.421
M08.422	M08.431	M08.432	M08.441	M08.442
M08.451	M08.452	M08.461	M08.462	M08.471

M08.472	M08.48	M08.811	M08.812	M08.821
M08.822	M08.831	M08.832	M08.841	M08.842
M08.851	M08.852	M08.861	M08.862	M08.871
M08.872	M08.88	M08.89	M08.9A	M08.921
M08.922	M08.931	M08.932	M08.941	M08.942
M08.951	M08.952	M08.961	M08.962	M08.971
M08.972	M08.98	M08.99	M25.511	M25.512
M25.521	M25.522	M25.531	M25.532	M25.541
M25.542	M25.551	M25.552	M25.561	M25.562
M25.571	M25.572	M25.611	M25.612	M25.621
M25.622	M25.631	M25.632	M25.641	M25.642
M25.651	M25.652	M25.661	M25.662	M25.671
M25.672	M25.674	M25.675	M62.81	M79.601
M79.602	M79.604	M69.605	M79.621	M79.622
M79.631	M79.632	M79.641	M79.642	M79.644
M79.645	M79.651	M79.652	M79.661	M79.662
M79.671	M79.672	M79.674	M79.674	M79.675
R29.4	R29.898	R53.0	R53.1	R53.81
R53.83	R63.0	R63.4	R68.2	Z00.01

Noncovered Services

Experimental/investigational (E/I) services are not covered regardless of place of service.

Selected testing for rheumatic disease is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a comorbid condition that would require monitoring in a more controlled environment such as the inpatient setting.

References

Mossell J, Goldman JA, Barken D, et al. The advise lupus test and cell-bound complement activation products aid the diagnosis of systemic lupus erythematosus. *Open Rheumatol J.* 2016;10:71-80.

Robinson WH, Mao R. Biomarkers to guide clinical therapeutics in rheumatology? *Curr Opin Rheumatol.* 2016;28(2):168-75.

Singh JA, Saag KG, Bridges SL, Jr., et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol.* 2016;68(1):1-26.

Birtane M, Yavuz S, Tastekin N. Laboratory evaluation in rheumatic diseases. *World J Methodol.* 2017 7:1–8. 10.5662

Myositis Autoantibodies. The Myositis Association. 2019.

Rheumatoid arthritis. Centers for Disease Control and Prevention Web site. Updated July 7, 2017.

Aringer M, Costenbader K, Daikh D, et al. 2019 european league against rheumatism/american college of rheumatology classification criteria for systemic lupus erythematosus. 2019;71(9):1400- 1412.